Show source-provided references
3. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease
10.1093/brain/awn016 ↗4. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: A prospective cohort study
10.1016/S1474-4422(12)70142-4 ↗10. (2021, February 13). GE Healthcare VizamylTM, Flutemetamol F 18 Injection. Available online: http://www3.gehealthcare.com/~/media/documents/us-global/products/nuclear-imaging-agents_non-gatekeeper/clinicalproductinfo/vizamyl/gehealthcare-vizamyl-prescribing-information.pdf.
11. Diagnostic accuracy of 18F amyloid PET tracers for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis
10.1007/s00259-015-3228-x ↗12. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: Statistical and pathological evaluation
10.1093/brain/awv112 ↗13. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer’s disease and cognitively normal subjects
10.2967/jnumed.111.090340 ↗14. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: Concordance with visual image reads
10.2967/jnumed.114.142109 ↗15. Imaging characteristic of dual-phase 18F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer’s disease and mild cognitive impairment
10.1007/s00259-016-3359-8 ↗16. Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios
10.2967/jnumed.114.148981 ↗17. Reference region selection and the association between the rate of amyloid accumulation over time and the baseline amyloid burden
10.1007/s00259-017-3666-8 ↗19. White matter reference region in PET studies of 11C-Pittsburgh compound B uptake: Effects of age and amyloid-β deposition
10.2967/jnumed.117.204271 ↗20. Appropriate reference region selection of 18F-florbetaben and 18F-flutemetamol beta-amyloid PET expressed in Centiloid
10.1038/s41598-020-70978-z ↗22. Application of Haralick texture features in brain [18F]-florbetapir positron emission tomography without reference region normalization
10.2147/CIA.S143307 ↗23. Diagnostic and prognostic value of amyloid PET textural and shape features: Comparison with classical semi-quantitative rating in 760 patients from the ADNI-2 database
10.1007/s11682-018-9833-0 ↗25. Friston, K.J., Ashburner, J., Kiebel, S., Nichols, T., and Penny, W.D. (2006). Statistical Parametric Mapping: The Analysis of Funtional Brain Images, Academic Press. [1st ed.].
26. Low-dose CT for the spatial normalization of PET images: A validation procedure for amyloid-PET semi-quantification
10.1016/j.nicl.2018.07.013 ↗27. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain
10.1006/nimg.2001.0978 ↗29. Asymmetries of amyloid-β burden and neuronal dysfunction are positively correlated in Alzheimer’s disease
10.1093/brain/awv229 ↗31. A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities
10.1088/0031-9155/60/14/5471 ↗34. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer’s disease dementia, mild cognitive impairment, and normal aging
10.1016/j.jalz.2012.10.007 ↗35. Hosmer, D.W., Lemeshow, S., and Sturdivant, R.X. (2013). Assessing the Fit of the Model. Applied Logistic Regression, John Wiley & Sons.
10.1002/9781118548387 ↗